Core Insights - Ocular Therapeutix will host a webcast on February 17, 2026, to review topline results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration [1] - Detailed data from the trial will be presented at the 49 Macula Society Annual Meeting from February 25 to 28, 2026 [1] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [3] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal diseases, currently in Phase 3 trials for wet AMD and diabetic retinal disease [3] - The company utilizes its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [4] Product Pipeline - DEXTENZA is approved for treating ocular inflammation and pain post-surgery and allergic conjunctivitis in patients aged two years or older [4] - Ocular is also developing OTX-TIC, a travoprost intracamreal hydrogel that has completed Phase 2 trials for open-angle glaucoma or ocular hypertension [4]

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study in moderate-t ...

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIKRA INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 13, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 1 FORM F-1 Cayman Islands 2833 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Unit 1.02, The Bouste ...

Core Viewpoint - Disc Medicine, Inc. announced that the FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for bitopertin, delaying its potential approval for treating erythropoietic protoporphyria (EPP) [1] Group 1: FDA Review and Approval Process - The FDA acknowledged that previous trials (AURORA and BEACON) provided sufficient evidence that bitopertin significantly lowers whole blood metal-free PPIX [2][6] - However, the FDA concluded that the trials did not demonstrate a clear association between the change in PPIX levels and clinical benefits related to sunlight exposure, necessitating further evidence from the ongoing APOLLO study for traditional approval [2][6] - The APOLLO study is expected to provide topline data in Q4 2026, which could serve as a basis for traditional approval [6] Group 2: Company Response and Future Plans - The company remains committed to delivering bitopertin to the EPP community and plans to pursue all avenues for FDA approval despite the CRL [3] - Disc Medicine is confident in the ongoing APOLLO trial, which has seen significant enthusiasm from patients and physicians, leading to early completion of trial enrollment in March 2026 [3] - Following the completion of the APOLLO study, the company plans to respond to the CRL and anticipates an updated FDA decision by mid-2027 [3] Group 3: Financial Position - As of December 31, 2025, Disc Medicine reported approximately $791 million in cash, cash equivalents, and marketable securities, providing a financial runway into 2029 [3]

Core Viewpoint - Nxera Pharma Co., Ltd. (OTC:SOLTF) is facing significant financial challenges despite its strategic progress in developing treatments for neurological conditions, as evidenced by its recent earnings report [1][6]. Financial Performance - The company reported an earnings per share (EPS) of -$0.54, which was significantly below the estimated EPS of $0.47, indicating ongoing struggles with profitability [2][6]. - Actual revenue for the period was approximately $49.6 million, falling short of the estimated $78.9 million, suggesting that the company is not meeting market expectations [3][6]. - The price-to-earnings (P/E) ratio of approximately -12.22 further highlights the negative earnings situation, indicating that the company is not currently generating profits [2]. - The price-to-sales ratio of about 2.62 indicates that investors are paying $2.62 for every dollar of sales, which may be seen as high given the revenue miss [3]. Liquidity and Debt Management - Nxera Pharma maintains a strong liquidity position, with a current ratio of approximately 3.14, suggesting the ability to cover short-term liabilities [4][6]. - The enterprise value to operating cash flow ratio of around -8.15 indicates difficulties in generating cash flow from operations, which could impact future growth and investment [4]. - The debt-to-equity ratio is about 0.96, suggesting a moderate level of debt relative to equity, which may be manageable but requires focus on improving profitability and cash flow for long-term stability [5].

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the previously projected timeline [2]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - On August 8, 2024, Inovio announced a delay in the submission of the INO-3107 BLA to mid-2025 due to manufacturing issues, resulting in a stock price drop of $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. Group 2: Regulatory Developments - On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 BLA for standard review rather than accelerated review, as the company did not provide adequate information for the latter [4]. - Following this announcement, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 on December 29, 2025 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to serve as lead plaintiff by April 7, 2026 [5].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing material adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show statistically significant improvement on the primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, and can choose to remain absent class members if they do not wish to participate [4].

Core Insights - Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, operating in a competitive biopharmaceutical industry alongside peers like Alnylam Pharmaceuticals, Amicus Therapeutics, ACADIA Pharmaceuticals, and Axsome Therapeutics [1] Financial Metrics Comparison - Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, significantly higher than its Weighted Average Cost of Capital (WACC) of 9.86%, resulting in a ROIC to WACC ratio of 2.11, indicating efficient capital utilization and potential for growth [2] - Alnylam Pharmaceuticals shows a negative ROIC of -10.44% against a WACC of 5.30%, leading to a ROIC to WACC ratio of -1.97, highlighting inefficiencies in capital utilization [3] - Amicus Therapeutics also reports a negative ROIC of -13.65% with a WACC of 6.20%, resulting in a ROIC to WACC ratio of -2.20, indicating challenges in generating returns above its cost of capital [3] - ACADIA Pharmaceuticals stands out with a ROIC of 23.32% and a WACC of 6.74%, yielding a ROIC to WACC ratio of 3.46, suggesting strong capital efficiency and growth potential [4] - Axsome Therapeutics has a notably negative ROIC of -55.37%, far below its WACC of 5.53%, resulting in a ROIC to WACC ratio of -10.02, indicating significant challenges in capital utilization [5][6]

Core Insights - AtaiBeckley Inc. (NASDAQ:ATAI) is identified as a strong buy penny stock with multiple bullish ratings from various firms, indicating positive market sentiment towards the company [1][2]. Group 1: Ratings and Price Targets - H.C. Wainwright maintains a Buy rating on AtaiBeckley Inc. with a price target of $15 [1]. - Guggenheim initiated a Buy rating with a price target of $11, highlighting the company's leadership in next-generation psychiatry and the significance of its merger with Beckley Psytech [2]. - JonesTrading reaffirmed a Buy rating with a price target of $16, emphasizing the company's market opportunity and upcoming pivotal Phase II results expected in 2026 [2]. Group 2: Clinical Development and Market Position - The merger with Beckley Psytech allows AtaiBeckley complete ownership of BPL-003, which has shown compelling efficacy in treating treatment-resistant depression [2]. - The lead compounds BPL-003 and VLS-01 are considered well-suited for treatment-resistant depression due to their short duration of action, aligning with a clinic-based model similar to esketamine [3]. - AtaiBeckley is positioned for a data-rich 2026, with significant clinical developments anticipated across its pipeline [2].

Biogen Conference Call Summary Company Overview - **Company**: Biogen (NasdaqGS:BIIB) - **Date**: February 13, 2026 - **Focus**: Immunology pipeline, specifically lupus treatments and other autoimmune diseases Key Points Industry Focus - **Lupus Treatment**: Biogen is prioritizing lupus, particularly systemic lupus erythematosus (SLE), due to its status as a major unmet medical need in drug development [2][5][11] - **Current Pipeline**: The company is developing two late-stage drugs, dapirolizumab and litifilimab, targeting lupus [1][2] Strategic Rationale - **Unmet Need**: Lupus is described as an underserved and heterogeneous disease area, with only 20%-30% of patients in the U.S. receiving biologic therapy [11][13] - **Long-term Commitment**: Biogen has been involved in lupus research for over a decade, indicating a long-term commitment to addressing this disease [5][7] Drug Development Insights - **Dapirolizumab and Litifilimab**: Both drugs aim to address limitations of existing treatments like belimumab and anifrolumab, with a focus on improving efficacy and reducing side effects [11][13] - **Patient-Centric Approach**: The company emphasizes the need for multiple treatment options due to the variability in lupus manifestations among patients [15][17] Mechanism of Action - **Litifilimab**: Targets BDCA2 receptors on plasmacytoid dendritic cells, which are involved in producing interferons that drive inflammation [19][21] - **Clinical Outcomes**: The drug has shown promise in improving overall disease control and specific manifestations like skin and joint symptoms [27][29] Clinical Trial Design - **Endpoints**: Different primary endpoints are used for dapirolizumab (BICLA response) and litifilimab (SRI-4), reflecting their unique mechanisms and patient needs [30][32] - **Durability of Effect**: Both drugs are designed to assess not only immediate efficacy but also the durability of treatment effects over time [52][54] Safety and Special Populations - **Pregnancy Considerations**: Dapirolizumab is noted for its potential safety in pregnant women, as it does not cross the placenta, which is a significant advantage given the demographic affected by lupus [63][65] Competitive Landscape - **Emerging Treatments**: The company acknowledges the upcoming readouts for other oral agents in lupus treatment, indicating a belief in a diverse treatment landscape rather than a winner-takes-all scenario [69][70] - **Future Pipeline**: Biogen is exploring additional oral therapies and has a robust early pipeline to expand treatment options [74] Broader Implications - **B-cell Biology**: The company is also interested in CD38 biology for autoimmune diseases, indicating a strategic focus on multiple indications beyond lupus [106][111] Additional Insights - **Patient Experience**: The discussion highlights the importance of addressing both physical and mental health impacts of lupus, emphasizing the need for effective treatment options that improve quality of life [29][65] - **Regulatory Engagement**: Biogen is actively engaging with regulatory agencies to explore pathways for the use of its therapies in special populations, such as pregnant women [68][69] This summary encapsulates the key discussions and insights from Biogen's conference call, focusing on their strategic direction in lupus treatment and the broader implications for the immunology field.